Novocure Ltd Ord Sh (NVCR) | |||
---|---|---|---|
15.63 0.99 (6.76%) | 03-28 16:00 | ||
Open: | 14.55 | Pre. Close: | 14.64 |
High: | 16.05 | Low: | 14.38 |
Volume: | 2,403,276 | Market Cap: | 1,674(M) |
Stock Technical Analysis | |
---|---|
Overall: | |
Target: | Six months: 21.07 One year: 24.61 |
Support: | Support1: 14.86 Support2: 12.90 |
Resistance: | Resistance1: 18.04 Resistance2: 21.07 |
Pivot: | 14.39 |
Moving Averages: | MA(5): 13.95 MA(20): 14.94 MA(100): 13.97 MA(250): 29.87 |
MACD: | MACD(12,26): -0.32 Signal(12,26,9): -0.32 |
%K %D: | %K(14,3): 30.09 %D(3): 16.11 |
RSI: | RSI(14): 56.91 |
52-Week: | High: 83.6 Low: 10.87 Change(%): -73.2 |
Average Vol(K): | 3-Month: 1405 10-Days: 2318 |
Prices Prediction (Update @5:00pm) | ||
---|---|---|
If tomorrow: | Open lower | Open higher |
High: | 16.077 - 16.154 | 16.154 - 16.224 |
Low: | 14.205 - 14.288 | 14.288 - 14.363 |
Close: | 15.485 - 15.63 | 15.63 - 15.761 |
Price, MAs and Bollinger Bands |
---|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVCR ] has closed below upper band by 20.4%. Bollinger Bands are 47.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue. |
Company profile |
---|
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. |
Stock chart |
---|
Stock News |
---|
Thu, 18 Jan 2024 Healthcare Stocks on the Move Thursday: MRAI, JSPR, NVCR, ELVN, RNAZ, PBLA, PRQR, CANO - InvestorsObserver Mon, 12 Jun 2023 3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon - InvestorPlace Fri, 29 Mar 2024 Fri, 29 Mar 2024 Fri, 29 Mar 2024 Fri, 29 Mar 2024 |
Financial Analysis | |
---|---|
Price to Book Value: | Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
Price to Earnings: | Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
Discounted cash flow: | Neutral |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
Return on Assets: | Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
Return on Equity: | Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
Debt to Equity: | Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Stock Basics & Statistics | |
---|---|
Exchange: NASDAQ Global Select | |
Sector: Healthcare | |
Industry: Medical - Instruments & Supplies | |
Shares Out. (M) | 107.09 |
Shares Float (M) | 95.92 |
% Held by Insiders | 1.67 |
% Held by Institutions | 85.97 |
Shares Short (K) | 5640 |
Shares Short Prior Month (K) | 5770 |
Stock Financials | |
---|---|
EPS | -1.950 |
Book Value (p.s.) | 3.380 |
Profit Margin | -40.65 |
Operating Margin | -33.64 |
Return on Assets (ttm) | -12.1 |
Return on Equity (ttm) | -51.5 |
Qtrly Rev. Growth | 4.2 |
Gross Profit (p.s.) | |
Sales Per Share | 4.756 |
EBITDA (p.s.) | -2.021 |
Qtrly Earnings Growth | |
Operating Cash Flow (M) | -73.34 |
Levered Free Cash Flow (M) | -10.20 |
Stock Valuation | |
---|---|
PE Ratio | -8.02 |
PEG Ratio | -0.13 |
Price to Book value | 4.62 |
Price to Sales | 3.29 |
Price to Cash Flow | -22.82 |
Stock Dividends | |
---|---|
Dividend | |
Dividend Yield | |
Dividend Growth |